Veeva Partners with BioMarin to Enhance Drug Development Efficiency

Written by Emily J. Thompson, Senior Investment Analyst

BMRN-2.32%

VEEV-0.43%

Source: PRnewswire

Updated: 14h ago

0mins

Source: PRnewswire

Strategic Partnership Upgrade: Veeva Systems has established a long-term agreement with BioMarin Pharmaceutical Inc. aimed at enhancing operational efficiency and market responsiveness through the strategic use of Veeva's software and services, thereby accelerating the development and commercialization of innovative therapies.
Digital Transformation Advancement: BioMarin's CEO Alexander Hardy stated that this collaboration will combine BioMarin's scientific expertise with Veeva's technological leadership, enabling transformative drugs to reach patients worldwide faster, significantly improving patient treatment experiences.
Industry Leadership Consolidation: Veeva, as a cloud service provider for the life sciences sector serving over 1,500 clients, not only enhances its influence in the biopharmaceutical field through this partnership but also further solidifies its market leadership position.
Positive Future Outlook: The collaboration is expected to drive innovation in BioMarin's gene disease treatments, with the company having eight commercial therapies and a robust clinical pipeline, likely providing patients with greater treatment options and hope.

BMRN

$58.95+Infinity%1D

Analyst Views on BMRN

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.50 USD with a low forecast of 55.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Analyst Rating

14 Buy

4 Hold

0 Sell

Strong Buy

Current: 60.350

Low

55.00

Averages

87.50

High

120.00

Current: 60.350

Low

55.00

Averages

87.50

High

120.00

Leerink

Joseph Schwartz

Outperform

Market Perform

downgrade

$17

2025-12-29

Reason

Leerink

Joseph Schwartz

Price Target

$17

2025-12-29

downgrade

Outperform

Market Perform

Reason

Leerink analyst Joseph Schwartz downgraded Amicus (FOLD) to Market Perform from Outperform with a price target of $14.50, down from $17, following the recently announced acquisition by BioMarin (BMRN). The firm views BioMarin is a good strategic fit and thinks it is unlikely that another bid will emerge.

Truist

Joon Lee

Buy

maintain

$80 -> $100

2025-12-23

Reason

Truist

Joon Lee

Price Target

$80 -> $100

2025-12-23

maintain

Buy

Reason

Truist analyst Joon Lee raised the firm's price target on BioMarin (BMRN) to $100 from $80 and keeps a Buy rating on the shares. The company's proposed acquisition of Amicus (FOLD) hits all the right notes based on the following, including two approved rare disease drugs aligns with BioMarin's rare disease focus, the analyst tells investors in a research note. The deal is also accretive within 12 months post close in Q2 and substantially accretive starting 2027 given that Amicus is a profitable biotech, Truist notes, adding that the combination having twice the size of greater geographic reach of BioMarin vs. Amicus could drive continued growth into relatively long exclusivity into 2037.

Oppenheimer

Outperform

initiated

$283

2025-12-23

Reason

Oppenheimer

Price Target

$283

2025-12-23

initiated

Outperform

Reason

Oppenheimer initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and $283 price target. Further to FDA's confirmation that existing and what the firm views as "compelling" clinical biomarker data could drive accelerated approval, recent Breakthrough Therapy designation bolsters the firm's conviction ahead of next year's anticipated approval for Sanfilippo type B syndrome, the analyst tells investors. The firm, which sees "considerable upside for this underappreciated story," adds that it believes BioMarin (BMRN) would be "a logical acquirer."

H.C. Wainwright

Neutral

maintain

$55 -> $60

2025-12-22

Reason

H.C. Wainwright

Price Target

$55 -> $60

2025-12-22

maintain

Neutral

Reason

H.C. Wainwright raised the firm's price target on BioMarin (BMRN) to $60 from $55 and keeps a Neutral rating on the shares. The firm views the company's acquisition of Amicus (FOLD as a "strategic move that secures long- term durability of cash flows but places the peak sales payoff firmly in the 2030s." The payoff to the Amicus deal is "far away," and until then, Voxzogo remains the focal point of BioMarin shares, the analyst tells investors in a research note.

About BMRN

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.